Clinical Trials
14 trialsNCT04217278 2026-05-05
COSI
University of Birmingham
Phase 2/3 Active not recruiting
NCT04708054 2026-02-19
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
M.D. Anderson Cancer Center
Phase 2/3 Recruiting
NCT07052422 2025-07-04
VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Not yet recruiting
NCT00630565 2024-01-29
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT01949129 2024-01-16
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
St. Anna Kinderkrebsforschung
Phase 2/3 Recruiting
NCT00003816 2021-08-13
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
Phase 2/3 Completed
NCT03530085 2020-12-22
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02671708 2020-03-03
IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Completed
NCT03385096 2020-02-25
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04123392 2019-10-10
Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT04098653 2019-09-23
Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT00176839 2017-12-05
Stem Cell Transplantation for Hematological Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2/3 Terminated
NCT03229616 2017-10-12
BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT00454480 2013-08-26
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
National Cancer Institute (NCI)
Phase 2/3 Completed